Clinical trial NCT02241915: Use of a Microbial Sealant to Reduce Surgical Site Infections.
Official title: Microbial Sealants Do Not Decrease Surgical Site Infection for Clean Contaminated Colorectal Procedures.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Surgical Site Infection
SCIP
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2014-09-16
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Surgical site infections (SSI) are costly complications that may cause significant morbidity and increase the cost of care, particularly in colorectal surgery. Microbial sealants (MS) are a new class of wound barriers aimed at decreasing SSI, however there is only evidence of benefit in clean Class 1 procedures. Based on its success in Class 1 procedures, we hypothesized that a microbial sealant could reduce the rate of SSI by half for clean contaminated colorectal procedures (Class 2).


Eligibility criteria: Inclusion Criteria:

1. Nonemergent colon and/or rectal abdominal surgical procedures
2. Women of child-bearing potential must have a negative serum HCG assay prior to surgery
3. Ages ≥18 years.

Exclusion Criteria:

1. Known history of hypersensitivity to cyanoacrylate, formaldehyde or acetone products.
2. Undergoing emergency surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed). Emergency surgery includes cases where standard bowel preparation and other preoperative assessments cannot be done.
3. Undergoing a significant concomitant surgical procedure (e.g., Whipple \& organ transplant surgery).

   The following concomitant procedures are allowed: appendectomy, cholecystectomy, oophorectomy, liver biopsy/wedge resection (but not liver resection), cystectomy.
4. History of prior laparotomy within the last 60 days of this planned procedure.
5. Planned to undergo a second laparotomy or colorectal surgical procedure (e.g. colostomy or ileostomy takedown) within 60 days of this planned first procedure.
6. Evidence preoperatively of any of the following: sepsis, severe sepsis, or septic shock (note that SIRS alone is not an exclusion criteria).6, 7
7. Preoperative severe neutropenia defined as total neutrophil count ≤500 × 106/L.
8. Current abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy or for any reason.
9. Receiving antibiotic therapy within the 1 week prior to the date of surgery.
10. Preoperative evaluation suggests intra-abdominal process that might preclude full closure of the skin.
11. Preoperative serum creatinine \> 3 mg/dL or renal failure requiring dialysis.
12. History of ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer.
13. History of major organ transplantation, including bone marrow transplantation.
14. Taking systemic steroids \>10 mg prednisone daily or remicade within 2 weeks prior to surgery or a history of a current immunosuppressive condition (eg, symptomatic HIV infection), defined as a CD4 count \< 200.
15. Pregnant, lactating, or of childbearing potential not practicing a birth control method with a high degree of reliability (defined in section 3.1).
16. Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated.

Primary outcomes:
measure: Incidence of SSI with and without microbial sealant.
timeFrame: 15 Months
Secondary outcomes:
measure: Subgroup incidence of SSI with and without microbial sealant
timeFrame: 15 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Los Angeles County/USC Medical Center
state: California
Study officials:
References: